MRNA FY2026 Q2 В пределах ожиданий

Отчётный звонок Moderna, Inc.

Jul 31, 2026 · 08:00 ET David BermanJamie MockLavina Talukdar earningscall_biz

Вывод Buzzberg

Norovirus phase 3 interim misses early success; fourth cohort to enroll

Moderna's Q2 2026 call was a steady-state update: the company beat quarterly revenue expectations, maintained its full-year guidance, and reduced cost forecasts. Major pipeline milestones remain the primary focus, with the crucial Phase 3 melanoma data for intesmorum expected in the second half of the year. Reported Q2 2026 revenue of $145M, beating the guidance range.

Вывод Buzzberg Norovirus phase 3 interim misses early success; fourth cohort to enroll Moderna's Q2 2026 call was a steady-state update: the company beat quarterly revenue expectations, maintained its full-year guidance, and reduced cost forecasts. Major pipeline milestones remain the primary focus, with the crucial Phase 3 melanoma data for intesmorum expected in the second half of the year. Reported Q2 2026 revenue of $145M, beating the guidance range. Читать полный анализСвернуть анализ

Reiterated full-year 2026 revenue growth guidance of up to 10%.
Lowered 2026 operating expense and cash cost guidance by $0.2B.
Flu vaccine (mRNA-1010) received a positive unanimous VRBPAC recommendation, ahead of an August 5th PDUFA date.

Выручка$0.145BФакт

EPS$-1.97+42% к/к

Валовая маржа35.86%Факт

Свободный денежный поток$-0.563B+19% к/к

6 подтверждённых тезисов

Что важно сейчас

Самые значимые изменения по итогам звонка.

Pipeline

Norovirus phase 3 interim misses early success; fourth cohort to enroll

Pipeline

INT melanoma phase 3 interim analysis expected in second half 2026

Regulatory

Flu vaccine receives unanimous VRBPAC recommendation; PDUFA August 5

Показать ещё 3 тезиса

Guidance

2026 cash cost guidance improved by $200 million to about $4 billion

Competitive Position

mRNA-1010 flu vaccine could enable late strain selection for 2027

Pipeline

RCC INT study could read out this year or next depending on events

Отчётный период

Фактические результаты

Показатель	Факт	Изменение
Выручка	$0.145B	Факт
EPS	$-1.97	+42% к/к
Валовая маржа	35.86%	Факт
Свободный денежный поток	$-0.563B	+19% к/к
Капзатраты	$0.037B	Факт
Чистая прибыль	$-0.782B	+42% к/к

Прогнозные данные

Прогноз компании

Показатель	Период	Диапазон	Середина	Статус
Капзатраты	FY2026	$0.2B–$0.3B	$0.25B	Подтверждён
Операционная маржа	FY2026	$4.7B	$4.7B	Понижен

AI, капзатраты и спрос

Оценка менеджмента

Тон

Measured Optimism

Management conveyed confidence in execution and pipeline progress while acknowledging misses (norovirus interim) and maintaining disciplined financial guidance.

Капзатраты

Инвестиции и мощности

Capital expenditures are still projected to be between $0.2 and $0.3 billion for 2026, with no change from prior guidance. The focus remains on operational efficiency and reducing cash costs rather than new capacity investments, though the company has established manufacturing capacity for a potential INT launch.

все упомянутые компании ниже: 3

Компаниис момента звонка

Партнёры

MRK 0.0%

Партнёры

Moderna's flu vaccine (mRNA-1010) has the capability to update its strain selection in under two months, a potential flexibility advantage over incumbent flu vaccines in response to late-season strain mismatches. — A late strain update capability could allow Moderna to offer a better-matched vaccine in a given season, potentially shifting market share from incumbent flu vaccine makers.

Доказательства

“And so, as you can imagine, Moderna and their Merck colleagues have been very active Stephen talked about manufacturing a minute ago, but they've been very active on the commercial side of the house in terms of medical affairs, marketing,”

Stéphane Bancel

Цепочка поставок

SNY +0.3%

Цепочка поставок

Доказательства

“Our demonstrated capability in the COVID context is less than two months, and so strain selections have happened as late as early July in the history of COVID and we've been able to make a fall vaccination season work with millions of”

Stephen Hoge

GSK +0.5%

Цепочка поставок

Moderna indicates that Europe will become a major growth driver starting in 2027, as an exclusive EU partnership from the pandemic era potentially expires, opening the door for their products. — Entry into the European market for COVID/flu vaccines would directly challenge incumbents Sanofi and GSK in a major market.

Доказательства

“So we really see Europe as a very important growth driver for us.”

Stéphane Bancel

Внешние сигналы

Альфа цепочки поставок · 3с момента звонка

Moderna's flu vaccine (mRNA-1010) has the capability to update its strain selection in under two months, a potential flexibility advantage over incumbent flu vaccines in response to late-season strain mismatches.

Stephen Hoge

MRK0.0%SNY+0.3%

Доказательства

“Our demonstrated capability in the COVID context is less than two months, and so strain selections have happened as late as early July in the history of COVID and we've been able to make a fall vaccination season work with millions of dose…”

Moderna indicates that Europe will become a major growth driver starting in 2027, as an exclusive EU partnership from the pandemic era potentially expires, opening the door for their products.

Stéphane Bancel

SNY+0.3%GSK+0.5%

Revenue growth for 2026 is largely pre-contracted, with the biggest U.S. variable being whether vaccination rate declines meet projections; any upside from a milder decline appears to flow directly to the top line.

Jamie Mock

Доказательства

“The biggest upside swing is if it is not as big a decline as we've projected, then we should have upside in the U.S.”

Методология и полнота

Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 3. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.